Hedtke Shannon M, Kuesel Annette C, Crawford Katie E, Graves Patricia M, Boussinesq Michel, Lau Colleen L, Boakye Daniel A, Grant Warwick N
Department of Physiology, Anatomy and Microbiology, La Trobe University, Bundoora, VIC, Australia.
Unicef/UNDP/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Geneva, Switzerland.
Front Genet. 2020 Jan 9;10:1282. doi: 10.3389/fgene.2019.01282. eCollection 2019.
Onchocerciasis and lymphatic filariasis are targeted for elimination, primarily using mass drug administration at the country and community levels. Elimination of transmission is the onchocerciasis target and global elimination as a public health problem is the end point for lymphatic filariasis. Where program duration, treatment coverage, and compliance are sufficiently high, elimination is achievable for both parasites within defined geographic areas. However, transmission has re-emerged after apparent elimination in some areas, and in others has continued despite years of mass drug treatment. A critical question is whether this re-emergence and/or persistence of transmission is due to persistence of local parasites-i.e., the result of insufficient duration or drug coverage, poor parasite response to the drugs, or inadequate methods of assessment and/or criteria for determining when to stop treatment-or due to re-introduction of parasites human or vector movement from another endemic area. We review recent genetics-based research exploring these questions in , the filarial nematode that causes onchocerciasis, and , the major pathogen for lymphatic filariasis. We focus in particular on the combination of genomic epidemiology and genome-wide associations to delineate transmission zones and distinguish between local and introduced parasites as the source of resurgence or continuing transmission, and to identify genetic markers associated with parasite response to chemotherapy. Our ultimate goal is to assist elimination efforts by developing easy-to-use tools that incorporate genetic information about transmission and drug response for more effective mass drug distribution, surveillance strategies, and decisions on when to stop interventions to improve sustainability of elimination.
盘尾丝虫病和淋巴丝虫病是消除的目标疾病,主要通过在国家和社区层面开展大规模药物给药来实现。消除传播是盘尾丝虫病的目标,而作为公共卫生问题的全球消除则是淋巴丝虫病的终点。在项目持续时间、治疗覆盖率和依从性足够高的地方,在规定的地理区域内这两种寄生虫的消除都是可以实现的。然而,在一些地区,传播在看似消除后又重新出现,而在其他地区,尽管进行了多年的大规模药物治疗,传播仍在继续。一个关键问题是,这种传播的重新出现和/或持续是由于当地寄生虫的持续存在,即持续时间或药物覆盖率不足、寄生虫对药物反应不佳、评估方法不足和/或确定何时停止治疗的标准不当的结果,还是由于寄生虫通过人类或病媒从另一个流行地区重新引入。我们回顾了最近基于遗传学的研究,这些研究探讨了导致盘尾丝虫病的丝状线虫和淋巴丝虫病的主要病原体中的这些问题。我们特别关注基因组流行病学和全基因组关联的结合,以划定传播区域,区分作为复发或持续传播来源的本地寄生虫和引入的寄生虫,并识别与寄生虫对化疗反应相关的遗传标记。我们的最终目标是通过开发易于使用的工具来协助消除工作,这些工具纳入有关传播和药物反应的遗传信息,以实现更有效的大规模药物分发、监测策略以及关于何时停止干预以提高消除可持续性的决策。